Prostate Cancer

Scientists have used artificial intelligence (AI) to reveal a new form of aggressive prostate cancer which they said could help thousands of lives by revolutionising how the disease is diagnosed and treated in the future. The study, published in the journal Cell Genomics, reveals that prostate cancer, which affects one in eight men in their lifetime, includes two different subtypes termed evotypes. The findings, led by researchers at the University of Oxford, and the University of Manchester, UK, could help provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI, they said. Our research demonstrates that prostate tumours evolve along multiple pathways, leading to two distinct disease types," said lead researcher Dan Woodcock, from the University of Oxford. This understanding is pivotal as it allows us to classify tumours based on how the cancer evolves rather than solely on individual gene mutations or expression ...

US Defense Secretary Lloyd Austin, who was diagnosed with prostate cancer in December, was hospitalised again on Sunday following symptoms pointing to an "emergent bladder issue", the Pentagon said. In a statement, the Pentagon said Austin was transported by his security detail to Walter Reed National Military Medical Center around 2.20 pm. While Austin initially was set to retain the "functions and duties of his office", at about 5 pm on Sunday he transferred those authorities to Deputy Secretary of Defense Kathleen Hicks. As of Sunday evening, he remained hospitalised, said Pentagon Press Secretary Maj Gen Pat Ryder. The chairman of the Joint Chiefs of Staff was also notified, as well as the White House and Congress. Ryder said Austin had travelled to the hospital with the unclassified and classified communications systems needed to perform his job. Austin was scheduled to depart on Tuesday for Brussels to hold a meeting of the Ukraine contact group, which he established in 2022

BDR stated since BDENZA is in liquid form, they can't quantify how lower it is compared to its counterparts in the market as they are present in solid form (tablet/capsule)

While there is strong evidence for the benefits of proton therapy in children, it is much less clear in prostate and other adult cancers.

Results can be particularly important for prostate patients who have risk factors for heart disease